Lupin and Amman Pharma Signs an Exclusive Agreement for Licensing and Supply of Ranibizumab (Biosimilar, Lucentis)
Shots:
- Lupin has entered an exclusive partnership with Amman Pharma for the marketing and commercialization of ranibizumab, biosimilar of Lucentis, in the Middle East region, incl. Jordan, Saudi Arabia, UAE, Iraq, Lebanon, & other GCC countries
- The biosimilar is indicated for the treatment of Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV)
- Ranibizumab is a recombinant humanized mAb fragment (IgG1) designed to bind to and block the activity of vascular endothelial growth factor A (VEGF-A)
Ref: Lupin | Image: Lupin
Related News:- Senju Pharmaceutical Highlighted Study Results of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
